keyword
MENU ▼
Read by QxMD icon Read
search

Oncology Updates

keyword
https://www.readbyqxmd.com/read/28644913/supplement-2-for-the-2004-update-of-the-aapm-task-group-no-43-report-joint-recommendations-by-the-aapm-and-gec-estro
#1
Mark J Rivard, Facundo Ballester, Wayne M Butler, Larry A DeWerd, Geoffrey S Ibbott, Ali S Meigooni, Christopher S Melhus, Michael G Mitch, Ravinder Nath, Panagiotis Papagiannis
Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Seed Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston)...
June 23, 2017: Medical Physics
https://www.readbyqxmd.com/read/28640707/response-assessment-in-neuro-oncology-clinical-trials
#2
Patrick Y Wen, Susan M Chang, Martin J Van den Bent, Michael A Vogelbaum, David R Macdonald, Eudocia Q Lee
Development of novel therapies for CNS tumors requires reliable assessment of response and progression. This requirement has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vascular permeability, such as antiangiogenic therapies. In addition, most tumors have a nonenhancing component that can be difficult to accurately quantify. To improve the response assessment in neuro-oncology and to standardize the criteria that are used for different CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established...
June 22, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28635657/selection-of-nucleic-acid-aptamers-targeting-tumor-cell-surface-protein-biomarkers
#3
REVIEW
Marie-Cécile Mercier, Monique Dontenwill, Laurence Choulier
Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific targets with high affinity and selectivity. They are selected via an iterative process known as 'selective evolution of ligands by exponential enrichment' (SELEX). Aptamers have been developed against numerous cancer targets and among them, many tumor cell-membrane protein biomarkers. The identification of aptamers targeting cell-surface proteins has mainly been performed by two different strategies: protein- and cell-based SELEX, when the targets used for selection were proteins and cells, respectively...
June 21, 2017: Cancers
https://www.readbyqxmd.com/read/28624466/resectable-clinical-n2-non-small-cell-lung-cancer-what-is-the-optimal-treatment-strategy-an-update-by-the-british-thoracic-society-lung-cancer-specialist-advisory-group
#4
Matthew Evison, Amelia Clive, Lianne Castle, Helen Powell, Rachel Thomas, Robert Buttery, Vidan Masani, Susan Harden, Doug West, Ian Woolhouse
Patients and clinicians are faced with uncertainty on the optimal treatment strategy for potentially resectable non-small cell lung cancer where there is clinical evidence of involvement of the ipsilateral mediastinum. Randomised controlled trials and meta-analyses have failed to demonstrate superiority of one bimodality strategy over another (chemotherapy plus surgery versus chemotherapy plus radiotherapy). One trial of trimodality treatment with chemotherapy, radiotherapy and surgery demonstrated an improvement in progression-free, but not overall, survival versus chemotherapy and radiotherapy...
June 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28622889/turning-the-tide-clinical-utility-of-pd-l1-expression-in-squamous-cell-carcinoma-of-the-head-and-neck
#5
REVIEW
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
The use of cytotoxic and/or targeted agents is the gold standard in first- and second-line treatment of metastatic head and neck cancer. Currently the focus of oncologic research is shifting to the implementation of immune checkpoint inhibitor regimens. Many trials are being performed evaluating the survival benefit of various PD-1/PD-L1 blocking antibodies in both solid and haematological malignancies. Also, evaluation of the predictive value of PD-L1 expression on tumour cells and immune cells is being explored...
July 2017: Oral Oncology
https://www.readbyqxmd.com/read/28607803/cellular-immunity-augmentation-in-mainstream-oncologic-therapy
#6
Daohong Chen, Xiaoshi Zhang
Anticancer immunotherapy has undergone a long evolving journey for decades, and has been dramatically applied to mainstream treatments in oncology in recent 5 years. This progress represents an advanced milestone following cytotoxic medicine and targeted therapy. Cellular immunity plays a pivotal role in the immune responses of hosts to tumor antigens. Such immunity is notably suppressed during neoplastic progression due to immuno-editing processes. Cellular immunity can also be selectively re-activated to combat malignancies while exploiting the advantages of contemporary scientific breakthroughs in molecular immunology and genetic engineering...
May 2017: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28600867/reply-to-the-hematology-oncology-pharmacy-association-alternative-viewpoint-on-the-2016-accp-pharmacotherapy-didactic-curriculum-toolkit
#7
Terry L Schwinghammer, Drayton A Hammond, Andrew J Crannage
On behalf of the 2016 ACCP Educational Affairs Committee, we appreciate the thoughtful Alternative Viewpoint of the Hematology/Oncology Pharmacy Association (HOPA) Task Force(1) to the 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit. The Toolkit(2) and its accompanying Commentary(3) are published online with the expectation that there will be periodic updates. ACCP plans to review the Toolkit every two to three years and will empanel a Task Force in fall 2017 to conduct the next review, anticipating an update in 2018...
June 10, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28596261/kidney-cancer-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#8
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P Bro, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Mayer Fishman, Thomas H Gallagher, John L Gore, Steven L Hancock, Michael R Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T Lam, Clayton Lau, M Dror Michaelson, Thomas Olencki, Phillip M Pierorazio, Elizabeth R Plimack, Bruce G Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, Rashmi Kumar
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28595812/beyond-imaging-the-promise-of-radiomics
#9
REVIEW
Michele Avanzo, Joseph Stancanello, Issam El Naqa
The domain of investigation of radiomics consists of large-scale radiological image analysis and association with biological or clinical endpoints. The purpose of the present study is to provide a recent update on the status of this rapidly emerging field by performing a systematic review of the literature on radiomics, with a primary focus on oncologic applications. The systematic literature search, performed in Pubmed using the keywords: "radiomics OR radiomic" provided 97 research papers. Based on the results of this search, we describe the methods used for building a model of prognostic value from quantitative analysis of patient images...
June 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28592771/ttp-and-ahus-new-insights
#10
Yoshitaka Miyakawa
Both TTP and aHUS are officially designated as intractable diseases by a new Japanese law in 2015. New clinical practice guidelines for TTP and aHUS have been published. Both conditions share some common pathophysiology such as thrombotic microangiopathy. Unfortunately, most professionals in the fields of hematology/oncology are unaware of these diseases. Therefore, I will provide an updated overview of TTP and aHUS in this article.
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28589623/impact-of-red-blood-cell-transfusion-strategies-in-haemato-oncological-patients-a-systematic-review-and-meta-analysis
#11
Marlijn P A Hoeks, Floris J Kranenburg, Rutger A Middelburg, Marian G J van Kraaij, Jaap-Jan Zwaginga
Haemato-oncological patients receive many red blood cell (RBC) transfusions, however evidence-based guidelines are lacking. Our aim is to quantify the effect of restrictive and liberal RBC transfusion strategies on clinical outcomes and blood use in haemato-oncological patients. A literature search, last updated on 11 August 2016, was performed in PubMed, EMBASE (Excerpta Medica Database), Web of Science, Cochrane, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Academic Search Premier without restrictions on language and year of publication...
June 7, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28585614/-advances-in-immunotherapy-for-metastatic-melanoma
#12
Judit Oláh
Improved understanding of melanoma genetics and immune regulatory pathways have culminated in the development of targeted and immunotherapies of the patients with metastatic melanoma. Recent advances in these oncological modalities have dramatically shifted this landscape with highly increased survival rates. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 based treatments (ipilimumab, nivolumab and pembrolizumab) have been an integral part of this therapeutic success. Nowadays the combined immune checkpoint inhibitor therapies have demonstrated a significant improvement in overall survival of patients with advanced melanoma...
June 6, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28579481/scientific-advances-in-thoracic-oncology-2016
#13
REVIEW
Ross A Soo, Emily Ca Stone, K Michael Cummings, James R Jett, John K Field, Harry Jm Groen, James L Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Dacic, Ramon Rami-Porta, Frank C Detterbeck, Eric Lim, Hisao Asamura, Jessica Donington, Heather A Wakelee, Yi Long Wu, Kristin Higgins, Suresh Senan, Benjamin Solomon, Dong-Wan Kim, Melissa Johnson, James Ch Yang, Lecia V Sequist, Alice T Shaw, Myung-Ju Ahn, Daniel B Costa, Jyoti D Patel, Leora Horn, Scott Gettinger, Solange Peters, Murry W Wynes, Corinne Faivre-Finn, Charles M Rudin, Anne Tsao, Paul Baas, Ronan J Kelly, Natasha B Leighl, Giorgio V Scagliotti, David R Gandara, Fred R Hirsch, David R Spigel
Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The IASLC and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for non-small cell lung cancer, small cell lung cancer, and mesothelioma...
May 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28577827/normal-tissue-constraints-for-abdominal-and-thoracic-stereotactic-body-radiotherapy
#14
REVIEW
Erqi L Pollom, Alexander L Chin, Maximilian Diehn, Billy W Loo, Daniel T Chang
Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology, experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577726/updates-in-hepatic-oncology-imaging
#15
REVIEW
Pallavi Pandey, Heather Lewis, Ankur Pandey, Carl Schmidt, Mary Dillhoff, Ihab R Kamel, Timothy M Pawlik
The utilization of advanced imaging modalities play an important role in the detection and differentiation of benign and malignant hepatic lesions. Imaging characteristics of hepatic tumors can sometimes be atypical, often leading to diagnostic challenges. Recent technical improvements in contrast enhanced ultrasound (CEUS), computed tomography (CT), and magnetic resonance imaging (MRI) have helped to better characterize hepatic lesions. For example, contrast agents used in US can now better delineate liver lesions, while the ability to reliably produce multiplanar and 3-D reconstructions through the use of MDCT provides an additional advantage in the context of therapeutic decision making for patients with hepatic lesions...
June 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28576188/update-of-practical-radiation-oncology-management-trends-for-surgeons
#16
EDITORIAL
Adam Raben
No abstract text is available yet for this article.
July 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28574778/do-the-american-society-of-clinical-oncology-value-framework-and-the-european-society-of-medical-oncology-magnitude-of-clinical-benefit-scale-measure-the-same-construct-of-clinical-benefit
#17
Sierra Cheng, Erica J McDonald, Matthew C Cheung, Vanessa S Arciero, Mahin Qureshi, Di Jiang, Doreen Ezeife, Mona Sabharwal, Alexandra Chambers, Dolly Han, Natasha Leighl, Kelley-Anne Sabarre, Kelvin K W Chan
Purpose Whether the ASCO Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCBS) measure similar constructs of clinical benefit is unclear. It is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommendations in the United Kingdom and Canada. Methods Randomized clinical trials of oncology drug approvals by the US Food and Drug Administration, European Medicines Agency, and Health Canada between 2006 and August 2015 were identified and scored using the ASCO version 1 (v1) framework, ASCO version 2 (v2) framework, and ESMO-MCBS by at least two independent reviewers...
June 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28561665/new-classification-for-central-nervous-system-tumors-implications-for-diagnosis-and-therapy
#18
Christine E Fuller, David T W Jones, Mark W Kieran
The 2016 World Health Organization Classification of Tumors of the Central Nervous System (WHO 2016) represents a noteworthy divergence from prior classification schemas. This new classification introduced the concept of "integrated diagnoses" based on a marriage of both phenotypic (microscopic) and genotypic parameters, with the intended goals of improving diagnostic accuracy and patient management. The result is a major restructuring in many of the brain tumor categories, with the codification of multiple new tumor entities and subgroups...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28549927/molecular-classification-of-adult-diffuse-gliomas-conflicting-idh1-idh2-atrx-and-1p-19q-results
#19
Leomar Y Ballester, Jason T Huse, Guilin Tang, Gregory N Fuller
Until recently, the diagnosis of brain tumors was primarily based on microscopic examination of hematoxylin and eosin (H&E) stained tissue sections. The updated World Health Organization (WHO) classification of tumours of the central nervous system (CNS) incorporates genetic alterations into the classification system, with the goal of creating more homogenous disease categories with greater prognostic value. Hence, under the new classification system the diagnosis of diffuse gliomas incorporates the evaluation of mutations in the IDH1 and IDH2 genes and simultaneous deletion of chromosomes 1p and 19...
May 23, 2017: Human Pathology
https://www.readbyqxmd.com/read/28547592/impact-of-interim-progression-during-the-surgery-to-radiotherapy-interval-and-its-predictors-in-glioblastoma-treated-with-temozolomide-based-radiochemotherapy
#20
Chan Woo Wee, Eunji Kim, Tae Min Kim, Chul-Kee Park, Jin Wook Kim, Seung Hong Choi, Roh-Eul Yoo, Soon-Tae Lee, Il Han Kim
This study was designed to investigate the impact of interim progression of disease (PD) during the surgery-to-radiotherapy interval (SRI) and its predictors in glioblastoma based on MRIs. A total of 222 patients were planned for radiotherapy (RT) and 166 of them were evaluable for the presence of interim PD by 2 separate MRIs. The size criteria from the updated Response Assessment in Neuro-Oncology criteria was adopted to determine interim PD. 32 (19.3%) patients experienced interim PD, and their median survival (MS) was shorter than patients without PD in univariate (11...
May 25, 2017: Journal of Neuro-oncology
keyword
keyword
25528
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"